Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29601744 | 0.87 | BACE1 (0.60) | CTSDBACE1 | |
| SCHEMBL10790323 | 0.87 | BACE1 (0.60) | CTSDBACE1 | |
| SCHEMBL7323888 | 0.85 | FCER2 (0.58) | CTSDBACE1 | |
| SCHEMBL30130747 | 0.85 | BACE1 (0.62) | CTSDBACE1 | |
| SCHEMBL30051333 | 0.84 | BACE1 (0.58) | CTSDBACE1 | |
| SCHEMBL1913895 | 0.83 | BACE1 (0.57) | CTSDBACE1 | |
| SCHEMBL13406831 | 0.82 | CTSD (0.60) | CTSDBACE1 | |
| SCHEMBL10826310 | 0.81 | LARS1 (0.54) | CTSD | |
| SCHEMBL5496815 | 0.81 | CTSD (0.59) | CTSDBACE1 | |
| SCHEMBL30052981 | 0.80 | LTA4H (0.66) | CTSDBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070248996-A1 | Modulators of beta-amyloid peptide aggregation comprising D-amino acids | PARAECIS PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | US | claimed |
| EP-1346041-B1 | THERAPEUTIC AGENTS AND METHODS OF USE THEREOF FOR TREATING AN AMYLOIDOGENIC DISEASE | PRAECIS PHARM INC (US) | 2007-02-28 | — | — | EP | claimed |
| US-20060014696-A1 | Modulators of beta-amyloid peptide aggregation comprising D-amino acids | PRAECIS PHARMACEUTICALS, INC. (US) | 2006-01-19 | — | — | US | claimed |
| EP-1586584-A1 | Modulators of beta-amyloid peptide aggregation comprising D-amino acids | Praecis Pharmaceuticals Incorporated (US) | 2005-10-19 | — | — | EP | claimed |
| EP-0929574-B1 | MODULATORS OF beta-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS | PRAECIS PHARM INC (US) | 2005-06-29 | — | — | EP | claimed |
| US-20020133001-A1 | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | PRAECIS PHARMACEUTICALS INC. | 2002-09-19 | — | — | US | claimed |
| US-20020103134-A1 | Modulators of beta-amyloid peptide aggregation comprising D-amino acids | PRAECIS PHARMACEUTICALS INC. | 2002-08-01 | — | — | US | claimed |
| US-6303567-B1 | FOR DIAGNOSIS AND THERAPY OF AMYLOIDOGENIC DISEASES SUCH AS ALZHEIMER'S DISEASE | PRAECIS PHARMACEUTICALS, INC . | 2001-10-16 | — | — | US | claimed |
| US-6277826-B1 | CONSISTING OF D-LEUCINE, D-PHENYLALANINE AND D-VALINE; PEPTIDE IS MODIFIED AT THE AMINO-TERMINUS, THE CARBOXY-TERMINUS, OR BOTH WITH AN AMIDE OR A HYDROXY GROUP | PRAECIS PHARMACEUTICALS, INC. | 2001-08-21 | — | — | US | claimed |
| US-5985242-A | PEPTIDE OF 3 TO 5 D-AMINO ACIDS; MAY BE MODIFIED AT AMINO-AND/OR CARBOXY TERMINUS; FOR TREATMENT OF AMYLOIDOSIS, ALZHEIMER'S DISEASE | PRAECIS PHARMACEUTICALS, INC. (US) | 1999-11-16 | — | — | US | claimed |
| EP-0929574-A1 | MODULATORS OF beta-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS | Praecis Pharmaceuticals Incorporated (US) | 1999-07-21 | — | — | EP | claimed |
| WO-1998008868-A9 | MODULATORS OF β-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS | — | 1998-05-28 | — | — | WO | claimed |
| WO-1998008868-A1 | MODULATORS OF β-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 1998-03-05 | — | — | WO | claimed |
| US-20070248996-A1 | Modulators of beta-amyloid peptide aggregation comprising D-amino acids | PARAECIS PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | US | disclosed |
| EP-1346041-B1 | THERAPEUTIC AGENTS AND METHODS OF USE THEREOF FOR TREATING AN AMYLOIDOGENIC DISEASE | PRAECIS PHARM INC (US) | 2007-02-28 | — | — | EP | disclosed |
| US-7175828-B2 | peptidic structure, preferably based on beta -amyloid peptide, that is composed entirely of D-amino acids that can bind to natural beta amyloid peptides ( beta -AP), modulate the aggregation of natural beta -AP and/or inhibit the neurotoxicity of natural beta -APs | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-5985242-A | PEPTIDE OF 3 TO 5 D-AMINO ACIDS; MAY BE MODIFIED AT AMINO-AND/OR CARBOXY TERMINUS; FOR TREATMENT OF AMYLOIDOSIS, ALZHEIMER'S DISEASE | PRAECIS PHARMACEUTICALS, INC. (US) | 1999-11-16 | — | — | US | disclosed |
| EP-0929574-A1 | MODULATORS OF beta-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS | Praecis Pharmaceuticals Incorporated (US) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998008868-A9 | MODULATORS OF β-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS | — | 1998-05-28 | — | — | WO | disclosed |
| WO-1998008868-A1 | MODULATORS OF β-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 1998-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070248996-A1 | Modulators of beta-amyloid peptide aggregation comprising D-amino acids | APP, IAPP, BACE1 | CTSD 1419/4885BACE1 3/4885 |
| US-20020103134-A1 | Modulators of beta-amyloid peptide aggregation comprising D-amino acids | IAPP, APP, VIP | CTSD 1392/4885BACE1 4/4885 |
| US-20060014696-A1 | Modulators of beta-amyloid peptide aggregation comprising D-amino acids | APP, IAPP, BACE1 | CTSD 1419/4885BACE1 3/4885 |
| US-20020133001-A1 | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | APP, CLN6, PSEN1 | CTSD 420/4885BACE1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.